Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states

By R. Cohn, C. V. Erp, J. Habashi, A. Soleimani, E. C. Klein, Matthew T. Lisi, Matthew Gamradt, C. Rhys, Tammy M. Holm, B. Loeys and 4 more. Nature Medicine, 2007

685 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0ab6519430d648a5e87139c3027dd6a336f56672

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. T. Ito
2. A. Uezumi
3. Daisuke Morikawa
4. Natsuko Shimizu
5. Tomohiro Yoneda
6. M. Segawa
7. Masahiko Yamaguchi
8. Ryo Ogawa

Citations in the corpus

• Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle (2011, background): “Losartan, a blocker of the angiotensin II type I receptor, is also a potent therapeutic drug for DMD. Cohn et al. reported that losartan attenuates TGF-binduced failure of skeletal muscle regeneration in mdx and fibrillin-null mice (Cohn et al., 2007).”